Biotech Business - April 5, 2023
STADA and Xbrane launch ranibizumab in Europe
Ranibizumab biosimilar is being launched in major European markets. Ranibizumab is the first product brought to market through a strategic collaboration between STADA and Xbrane Biopharma, marking Xbrane’s first commercial launch and STADA’s first co-development asset, in its growing biosimilars portfolio. Developed and manufactured solely in Europe, ranibizumab is the sixth biosimilar marketed in Europe […]
Biotech Business - April 5, 2023
Elypta awarded 1 MUSD Grand Prize from The Roddenberry Foundation
The Roddenberry Foundation has announced the six awardees of its biennial 1.5 million USD Prize to support audacious early-stage science and technology ventures that contribute to the United Nations Development Goals (UN SDGs). The 2023 Grand Prize (1 MUSD) has been awarded to Elypta for their development of the first metabolism-based test for early cancer […]
Biotech Business - April 5, 2023
Alligator announces authorization to initiate Phase 2 trial
Alligator Bioscience has announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application, allowing the company to initiate the OPTIMIZE-2 Phase 2 trial evaluating its lead asset mitazalimab in urothelial carcinoma. This open-label, multi-center study aims to assess the safety and efficacy of an immunotherapeutic combination of […]
Biotech Business - April 4, 2023
Gedea Biotech awarded 3 million SEK
The company has been awarded a grant from the Swedish innovation programs, SWElife and MedTech4Health in a collaboration with Danderyd hospital, Huddinge hospital and Karolinska Institute. The grant will fund a further clinical trial of its antibiotic free treatment pHyph for the treatment of vulvovaginal candida infections (VVC). The new study, involving 26 patients with VVC […]
Biotech Business - April 4, 2023
Modus has secured access to bridge financing of up to 7 MSEK
Modus Therapeutics secures access to bridge financing from longstanding investor Karolinska Development. Access to this funding ensures that momentum of clinical development of Modus’ lead asset, sevuparin, will be enhanced while the company continues to explore licensing and partnership opportunities, it states. These future development plans include preparation for a Phase 2a study evaluating sevuparin […]
Biotech Business - April 3, 2023
Oncopeptides receives a research grant from Vinnova
Oncopeptides has received a research grant of 3 million SEK from Sweden’s Innovation Agency (Vinnova), to explore the development of new treatment options for glioblastoma, an aggressive and incurable form of brain cancer. The grant enables exploratory research to better understand the potential of the PDC platform in solid tumors such as glioblastoma. “We are […]
